RELVAR ELLIPTA 184 mcg/22 mcg INHALATION POWDER (UNIDODIS)
How to use RELVAR ELLIPTA 184 mcg/22 mcg INHALATION POWDER (UNIDODIS)
Translated with AI
This page provides general information and does not replace a doctor’s consultation. Always consult a doctor before taking any medication. Seek urgent medical care if symptoms are severe.
Show originalContents of the leaflet
Introduction
Package Leaflet: Information for the Patient
Relvar Ellipta 92 micrograms/22 micrograms inhalation powder (single dose)
Relvar Ellipta 184 micrograms/22 micrograms inhalation powder (single dose)
fluticasone furoate/vilanterol
Read all of this leaflet carefully before you start using this medicine because it contains important information for you.
- Keep this leaflet, you may need to read it again.
- If you have any further questions, ask your doctor, pharmacist, or nurse.
- This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
- If you get any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in this leaflet. See section 4.
Contents of the pack
- What Relvar Ellipta is and what it is used for
- What you need to know before you use Relvar Ellipta
- How to use Relvar Ellipta
- Possible side effects
- Storing Relvar Ellipta
- Contents of the pack and other information
Step-by-step instructions for use
1. What Relvar Ellipta is and what it is used for
Relvar Ellipta contains two active substances: fluticasone furoate and vilanterol. There are two different strengths of Relvar Ellipta: fluticasone furoate 92 micrograms/vilanterol 22 micrograms and fluticasone furoate 184 micrograms/vilanterol 22 micrograms.
The 92/22 micrograms strength is used for the regular treatment of chronic obstructive pulmonary disease (COPD) in adults, as well as for the treatment of asthma in adults and adolescents aged 12 years and older.
The 184/22 micrograms strength is used for the treatment of asthma in adults and adolescents aged 12 years and older.
The 184/22 micrograms strength is not approved for the treatment of COPD.
Relvar Ellipta should be used every day and not just when you have difficulty breathing or other symptoms of asthma and COPD. It should not be used to relieve a sudden attack of breathlessness or wheezing. If you have this type of attack, you should use a fast-acting “rescue” inhaler (such as salbutamol). Contact your doctor if you do not have a fast-acting inhaler.
Fluticasone furoate belongs to a group of medicines called corticosteroids, often simply called steroids. Corticosteroids reduce inflammation. They also reduce swelling (inflammation) and irritation of the small airways in the lungs and gradually relieve breathing problems. Corticosteroids also help prevent asthma attacks and worsening of COPD.
Vilanterol belongs to a group of medicines called long-acting bronchodilators. It works by relaxing the muscles of the small airways in the lungs. This helps to open up the airways and makes it easier to breathe in and out. When used regularly, it helps to keep the small airways in the lungs open.
Using these two active substances together regularly will help you control your breathing problems better than either medicine on its own.
Asthmais a serious, chronic lung disease in which the muscles around the smaller airways tighten (bronchoconstriction) and become inflamed (inflammation). Symptoms come and go and include difficulty breathing, wheezing, chest tightness, and coughing. Relvar Ellipta has been shown to reduce asthma attacks and symptoms.
Chronic obstructive pulmonary disease (COPD)is a serious, chronic lung disease in which the airways become inflamed and thickened. Symptoms include difficulty breathing, coughing, chest discomfort, and coughing up mucus. Relvar Ellipta has been shown to reduce flare-ups of symptoms associated with COPD.
2. What you need to know before you use Relvar Ellipta
Do not use Relvar Ellipta
- if you are allergicto fluticasone furoate, vilanterol, or any of the other ingredients of this medicine (listed in section 6)
Warnings and precautions
Talk to your doctor before you start using Relvar Ellipta:
- if you have liver problems, as you may be more likely to have side effects. If you have moderate or severe liver problems, your doctor will limit your dose to the lowest strength of Relvar Ellipta (92/22 micrograms once daily)
- if you have heart problemsor high blood pressure
- if you have pulmonary tuberculosis (TB)or any other long-standing or untreated infection
- if you have ever been told you have diabetes or high blood sugar levels
- if you have thyroid problems
- if you have low potassium levels in your blood
- if you have blurred vision or other vision problems.
Talk to your doctorbefore using this medicine if you think any of the above applies to you.
While you are using Relvar Ellipta
Immediate breathing problems
If you have chest tightness, coughing, wheezing, or difficulty breathing immediately after using your Relvar Ellipta inhaler:
stop using this medicineandseek medical help immediately, as you may have a serious condition called paradoxical bronchospasm.
- Talk to your doctor if you have blurred vision or other vision problems.
- Talk to your doctor if you have increased thirst, frequent urination, or unexplained tiredness (signs of high blood sugar levels).
Lung infection
If you are using this medicine for COPD, you may be at a higher risk of developing a lung infection called pneumonia. See section 4 for information on symptoms to look out for while you are using this medicine. Talk to your doctor as soon as possible if you develop any of these symptoms.
Children and adolescents
Do not give this medicine to children under 12 years of age for the treatment of asthma, or to children and adolescents of any age for the treatment of COPD.
Other medicines and Relvar Ellipta
Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines. Talk to your doctor or pharmacist if you are not sure what your medicine contains.
Some medicines may affect the way this medicine works, or make it more likely that you will have side effects. These include:
- medicines called beta-blockers, such as metoprolol, used to treat high blood pressureor heart disease
- ketoconazole, used to treat fungal infections
- ritonavir or cobicistat, used to treat HIV
- long-acting beta2-adrenergic agonists, such as salmeterol.
Talk to your doctor or pharmacistif you are taking any of these medicines.
Some medicines may increase the effects of Relvar Ellipta, so your doctor may want to monitor you closely if you are taking these medicines.
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, think you may be pregnant, or are planning to have a baby, ask your doctor for advice before taking this medicine. If you are pregnant, do not use this medicine unless your doctor tells you to.
It is not known if this medicine passes into breast milk. Talk to your doctorbefore using Relvar Ellipta if you are breastfeeding. If you are breastfeeding, do not use this medicine unless your doctor tells you to.
Driving and using machines
It is unlikely that this medicine will affect your ability to drive or use machines.
Relvar Ellipta contains lactose
If your doctor has told you that you have an intolerance to some sugars, talk to your doctor before using this medicine.
3. How to use Relvar Ellipta
Always use this medicine exactly as your doctor has told you.If you are not sure, talk to your doctor or pharmacist.
Asthma
The recommended dosefor the treatment of asthma is one inhalation (92 micrograms of fluticasone furoate and 22 micrograms of vilanterol) once daily, at the same time each day.
If you have severe asthma, your doctor may decide that you should use one inhalation of the inhaler containing the higher strength (184 micrograms of fluticasone furoate and 22 micrograms of vilanterol). This dose is also used once daily, at the same time each day.
COPD
The recommended dosefor the treatment of COPD is one inhalation (92 micrograms of fluticasone furoate and 22 micrograms of vilanterol) once daily, at the same time each day.
The higher strength of Relvar Ellipta (184 micrograms of fluticasone furoate and 22 micrograms of vilanterol) is not suitable for the treatment of COPD.
Relvar Ellipta is inhaled through the mouth.
Use Relvar Ellipta at the same time each day, as it is effective for 24 hours
It is very important that you use this medicine every day, as prescribed by your doctor. This will help you to not have symptoms during the day or night.
Relvar Ellipta should not be used to relieve a sudden attack of breathlessness or wheezing. If you have this type of attack, you should use a fast-acting “rescue” inhaler (such as salbutamol).
If you feel like you are getting breathless or wheezing more often than usual, or if you are using your fast-acting “rescue” inhaler more often than usual, talk to your doctor.
How to use Relvar Ellipta
For full instructions on how to use Relvar Ellipta, see the step-by-step instructions at the end of this leaflet.
Relvar Ellipta is ready to use as soon as it is removed from its foil tray. You do not need to prepare it in any way.
If your symptoms do not improve
If your symptoms (breathlessness, wheezing, coughing) do not improve or get worse, or if you are using your fast-acting “rescue” inhaler more often than usual: talk to your doctor as soon as possible.
If you use more Relvar Ellipta than you should
If you accidentally inhale more Relvar Ellipta than your doctor has prescribed, talk to your doctor or pharmacist. If possible, show them your inhaler, packaging, or this leaflet. You may notice that your heart is beating faster than usual, feel shaky, or have a headache.
If you have used more medicine than you should for a long time, it is especially important that you talk to your doctor or pharmacist.This is because higher doses of Relvar Ellipta may reduce the amount of steroid hormones produced by your body.
If you forget to use Relvar Ellipta
Do not inhale a double dose to make up for a forgotten dose.Take your next dose at the usual time.
If you have wheezing or breathlessness, or develop any other symptoms of an asthma attack, use your fast-acting “rescue” inhaler(such as salbutamol), and talk to your doctor.
Do not stop using Relvar Ellipta without talking to your doctor
Use this medicine for as long as your doctor tells you to. It will only work if you use it every day. Do not stop using it unless your doctor tells you to, even if you feel better.
If you have any questions about using Relvar Ellipta, ask your doctor, pharmacist, or nurse.
4. Possible side effects
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Allergic reactions
Allergic reactions are rare (may affect up to 1 in 1,000 people)
If you have any of the following symptoms after using Relvar Ellipta, stop using this medicine and talk to your doctor immediately:
- skin rash (hives) or redness
- swelling, sometimes of the face or mouth (angioedema)
- wheezing, coughing, or difficulty breathing
- a sudden feeling of weakness or dizziness (which may cause collapse or loss of consciousness).
Immediate breathing problems
Immediate breathing problems after using Relvar Ellipta are rare.
If your breathing or wheezing gets worse immediately after using this medicine, stop using itand seek medical help immediately.
Pneumonia (lung infection)in patients with COPD (common side effect, may affect up to 1 in 10 people).
If you have any of the following symptoms while using Relvar Ellipta, talk to your doctor. They could be symptoms of a lung infection:
- fever or chills
- increase in mucus production, change in mucus color
- increase in coughing or difficulty breathing.
Other side effects:
Very common side effects
May affect more than 1 in 10 people:
- headache
- common cold.
Common side effects
May affect up to 1 in 10 people:
- thrush (candidiasis), a fungal infection of the mouth or throat. Rinsing your mouth with water immediately after using Relvar Ellipta may help prevent this side effect
- bronchitis (inflammation of the airways)
- sinus or throat infections
- flu
- pain or irritation in the back of the mouth and throat
- sinusitis (inflammation of the sinuses)
- itching, runny nose, or stuffy nose
- coughing
- changes in your voice
- weakening of the bones, which may cause fractures
- stomach pain
- back pain
- fever
- joint pain
- muscle spasms.
Uncommon side effects
May affect up to 1 in 100 people:
- irregular heartbeat
- blurred vision
- high blood sugar levels (hyperglycaemia).
Rare side effects
May affect up to 1 in 1,000 people:
- fast heartbeat (tachycardia)
- awareness of your heartbeat (palpitations)
- shakiness
- anxiety.
Reporting of side effects
If you get any side effects, talk to your doctor, pharmacist, or nurse.This includes any possible side effects not listed in this leaflet.You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.
5. Storing Relvar Ellipta
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton, tray, and inhaler after EXP. The expiry date is the last day of the month stated.
Keep the inhaler in the foil tray to protect it from moisture. Only remove the inhaler from the foil tray immediately before you use it for the first time. Once you have opened the foil tray, the inhaler can be used for 6 weeks. Write the date you open the foil tray on the inhaler label in the space provided. You should write the date in the space provided as soon as you remove the inhaler from the foil tray.
Do not store above 25°C.
If you store it in the refrigerator, let the inhaler come to room temperature for at least one hourbefore you use it.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help protect the environment.
6. Container contents and additional information
Composition of Relvar Ellipta
- The active ingredients are fluticasone furoate and vilanterol.
- For the 92/22 microgram dose: each inhalation provides a delivered dose (dose that comes out of the mouthpiece) of 92 micrograms of fluticasone furoate and 22 micrograms of vilanterol (as trifenatate).
- For the 184/22 microgram dose: each inhalation provides a delivered dose (dose that comes out of the mouthpiece) of 184 micrograms of fluticasone furoate and 22 micrograms of vilanterol (as trifenatate).
- The other ingredients are lactose monohydrate (see section 2 “Relvar Ellipta contains lactose”) and magnesium stearate.
Appearance of the product and container contents
Relvar Ellipta is a powder for inhalation (single-dose).
The Ellipta inhaler is a light grey inhaler with a yellow mouthpiece cover and a dose counter. It is packaged in a laminated aluminium foil tray with a flip-top lid. The tray contains a desiccant sachet to reduce moisture in the container. Once the lid of the tray is opened, discard the desiccant, do not ingest or inhale it. The inhaler does not need to be stored in the laminated aluminium foil tray once it has been opened.
Relvar Ellipta is available in packs of one inhaler containing 14 or 30 doses (for a 14 or 30-day treatment) and in clinical packs of 90 doses (3 inhalers of 30 doses, for a 90-day treatment). Not all pack sizes may be marketed.
Marketing authorisation holder:
GlaxoSmithKline Trading Services Limited
12 Riverwalk
Citywest Business Campus
Dublin 24
Ireland
D24 YK11
Manufacturer:
Glaxo Wellcome Production
Zone Industrielle No.2
23 Rue Lavoisier
27000 Evreux
France
You can request more information about this medicinal product from the local representative of the marketing authorisation holder:
België/Belgique/Belgien GlaxoSmithKline Pharmaceuticals s.a./n.v. Tél/Tel: + 32 (0) 10 85 52 00 | Lietuva UAB “BERLIN-CHEMIE MENARINI BALTIC” Tel: +370 52 691 947 |
| Luxembourg/Luxemburg GlaxoSmithKline Pharmaceuticals s.a./n.v. Belgique/Belgien Tél/Tel: + 32 (0) 10 85 52 00 |
Ceská republika GlaxoSmithKline s.r.o. Tel: + 420 222 001 111 | Magyarország Berlin-Chemie/A. Menarini Kft. Tel.: +36 23501301 |
Danmark GlaxoSmithKline Pharma A/S Tlf: + 45 36 35 91 00 | Malta GlaxoSmithKline Trading Services Limited Tel: +356 80065004 |
Deutschland BERLIN-CHEMIE AG Tel: +49 (0) 30 67070 | Nederland GlaxoSmithKline BV Tel: + 31 (0) 33 2081100 |
Eesti OÜ Berlin-Chemie Menarini Eesti Tel: +372 667 5001 | Norge GlaxoSmithKline AS Tlf: + 47 22 70 20 00 |
Ελλáδα Menarini Hellas A.E. Τηλ: +30 210 83161 11-13 | Österreich GlaxoSmithKline Pharma GmbH Tel: + 43 (0)1 97075 0 |
España GlaxoSmithKline, S.A. Tel: + 34 900 202 700 | Polska GSK Services Sp. z o.o. Tel.: + 48 (0)22 576 9000 |
France Laboratoire GlaxoSmithKline Tél.: + 33 (0)1 39 17 84 44 Hrvatska Berlin-Chemie Menarini Hrvatska d.o.o. Tel: +385 1 4821 361 | Portugal GlaxoSmithKline – Produtos Farmacêuticos, Lda. Tel: + 351 21 412 95 00 România GlaxoSmithKline Trading Services Tel: +40 800672524 |
Ireland GlaxoSmithKline Trading Services Limited Tel: + 353 (0)1 4955000 | Slovenija Berlin-Chemie / A. Menarini Distribution Ljubljana d.o.o. Tel: +386 (0)1 300 2160 |
Ísland Vistor hf. Sími: + 354 535 7000 | Slovenská republika Berlin-Chemie / A. Menarini Distribution Slovakia s.r.o. Tel: +421 2 544 30 730 |
Italia GlaxoSmithKline S.p.A. Tel: + 39 (0)45 7741111 | Suomi/Finland GlaxoSmithKline Oy Puh/Tel: + 358 (0)10 30 30 30 |
Κúπρος GlaxoSmithKline Trading Services Limited Τηλ: +357 80070017 | Sverige GlaxoSmithKline AB Tel: + 46 (0)8 638 93 00 |
Latvija SIA Berlin-Chemie/Menarini Baltic Tel: +371 67103210 | |
Date of last revision of this leaflet:
Other sources of information
Detailed information on this medicinal product is available on the European Medicines Agency website: http://www.ema.europa.eu.
Step-by-step instructions for use
What is the Ellipta inhaler?
The first time you use Relvar Ellipta, you do not need to check that it is working correctly, it is ready to use straight away. Just follow these step-by-step instructions.
The inhaler is packaged in a tray. Do not open the tray until you are ready to start using your new medicine. When you are ready to use your inhaler, remove the lid to open the tray. The tray contains a desiccantsachet, to reduce moisture. Discard the desiccant sachet, do not open, ingest or inhale it.
When you take the inhaler out of the tray, it will be in the “closed” position. Do not open the inhaleruntil you are readyto inhale a dose of medicine.When the tray is opened, you should write the “Discard by” date on the inhaler label (6 weeks from the date of opening the tray). After this date, the inhaler should not be used. The tray can be discarded after first opening.
If stored in a refrigerator, allow the inhaler to reach room temperature for at least 1 hour before use.
The step-by-step instructions for the 30-dose Ellipta inhaler (30 days of treatment) also apply to the 14-dose Ellipta inhaler (14 days of treatment).
- Read the following instructions before using the inhaler
If you open and close the cover without inhaling the medicine, you will lose a dose.
The lost dose will be safely retained inside the inhaler, but it will not be available for inhalation.
It is not possible to accidentally take an extra dose or double dose through a single inhalation.
- Prepare a dose
Before opening the cover, wait until you are ready to inhale a dose. Do not shake the inhaler.
- Slide the cover down until you hear a “click”.
The medicine is now ready to be inhaled.
As confirmation, the dose counter decreases by 1unit.
- If the dose counter does not decrease when you hear the “click”, the inhaler will not release the medicine.Take it back to your pharmacist and ask for help.
- Inhale the medicine
- Hold the inhaler away from your mouth, breathe out as much as is comfortable. Do notbreathe out into the inhaler.
- Put the mouthpiece between your lips, and close your lips firmly around the mouthpiece.Do notblock the ventilation slots with your fingers.
- Breathe in slowly and deeply through the mouthpiece. Hold your breath for as long as is comfortable (at least 3-4 seconds).
- Take the inhaler out of your mouth.
- Breathe out slowly and gently.
You may not be able to taste or feel the medicine, even when you use the inhaler correctly.
If you want to clean the mouthpiece, use a dry tissuebefore closing the cover.
- Close the inhaler and rinse your mouth
- Slide the cover back up as far as it will go to cover the mouthpiece.
- Rinse your mouth with water, after using the inhaler, do not swallow.
This will make it less likely that you will experience side effects such as mouth or throat ulcers.
- Country of registration
- Average pharmacy price44.8 EUR
- Active substance
- Prescription requiredYes
- Manufacturer
- This information is for reference only and does not constitute medical advice. Always consult a doctor before taking any medication. Oladoctor is not responsible for medical decisions based on this content.
- Alternatives to RELVAR ELLIPTA 184 mcg/22 mcg INHALATION POWDER (UNIDODIS)Dosage form: PULMONARY INHALATION, 92 micrograms/22 microgramsActive substance: vilanterol and fluticasone furoateManufacturer: Glaxosmithkline (Ireland) LimitedPrescription requiredDosage form: PULMONARY INHALATION, 184 micrograms/22 microgramsActive substance: vilanterol and fluticasone furoateManufacturer: Glaxosmithkline (Ireland) LimitedPrescription requiredDosage form: PULMONARY INHALATION, 92 micrograms/22 microgramsActive substance: vilanterol and fluticasone furoateManufacturer: Glaxosmithkline (Ireland) LimitedPrescription required
Online doctors for RELVAR ELLIPTA 184 mcg/22 mcg INHALATION POWDER (UNIDODIS)
Discuss questions about RELVAR ELLIPTA 184 mcg/22 mcg INHALATION POWDER (UNIDODIS), including use, safety considerations and prescription review, subject to medical assessment and local regulations.
Frequently Asked Questions
